511 related articles for article (PubMed ID: 33376625)
1. ALKBH5 Inhibited Cell Proliferation and Sensitized Bladder Cancer Cells to Cisplatin by m6A-CK2α-Mediated Glycolysis.
Yu H; Yang X; Tang J; Si S; Zhou Z; Lu J; Han J; Yuan B; Wu Q; Lu Q; Yang H
Mol Ther Nucleic Acids; 2021 Mar; 23():27-41. PubMed ID: 33376625
[TBL] [Abstract][Full Text] [Related]
2. RNA demethylase ALKBH5 prevents pancreatic cancer progression by posttranscriptional activation of PER1 in an m6A-YTHDF2-dependent manner.
Guo X; Li K; Jiang W; Hu Y; Xiao W; Huang Y; Feng Y; Pan Q; Wan R
Mol Cancer; 2020 May; 19(1):91. PubMed ID: 32429928
[TBL] [Abstract][Full Text] [Related]
3. ALKBH5-HOXA10 loop-mediated JAK2 m6A demethylation and cisplatin resistance in epithelial ovarian cancer.
Nie S; Zhang L; Liu J; Wan Y; Jiang Y; Yang J; Sun R; Ma X; Sun G; Meng H; Xu M; Cheng W
J Exp Clin Cancer Res; 2021 Sep; 40(1):284. PubMed ID: 34496932
[TBL] [Abstract][Full Text] [Related]
4. Down-regulated FTO and ALKBH5 co-operatively activates FOXO signaling through m6A methylation modification in HK2 mRNA mediated by IGF2BP2 to enhance glycolysis in colorectal cancer.
Ye M; Chen J; Lu F; Zhao M; Wu S; Hu C; Yu P; Kan J; Bai J; Tian Y; Tang Q
Cell Biosci; 2023 Aug; 13(1):148. PubMed ID: 37580808
[TBL] [Abstract][Full Text] [Related]
5. The m6A demethylase ALKBH5 promotes tumor progression by inhibiting RIG-I expression and interferon alpha production through the IKKε/TBK1/IRF3 pathway in head and neck squamous cell carcinoma.
Jin S; Li M; Chang H; Wang R; Zhang Z; Zhang J; He Y; Ma H
Mol Cancer; 2022 Apr; 21(1):97. PubMed ID: 35395767
[TBL] [Abstract][Full Text] [Related]
6. Loss of m6A demethylase ALKBH5 promotes post-ischemic angiogenesis via post-transcriptional stabilization of WNT5A.
Zhao Y; Hu J; Sun X; Yang K; Yang L; Kong L; Zhang B; Li F; Li C; Shi B; Hu K; Sun A; Ge J
Clin Transl Med; 2021 May; 11(5):e402. PubMed ID: 34047466
[TBL] [Abstract][Full Text] [Related]
7. USF1-mediated ALKBH5 stabilizes FLII mRNA in an m6A-YTHDF2-dependent manner to repress glycolytic activity in prostate adenocarcinoma.
Fu D; Si Q; Yu C; Han Z; Zang L
Mol Carcinog; 2023 Nov; 62(11):1700-1716. PubMed ID: 37493109
[TBL] [Abstract][Full Text] [Related]
8. ALKBH5 regulates STAT3 activity to affect the proliferation and tumorigenicity of osteosarcoma via an m6A-YTHDF2-dependent manner.
Yang Z; Cai Z; Yang C; Luo Z; Bao X
EBioMedicine; 2022 Jun; 80():104019. PubMed ID: 35490460
[TBL] [Abstract][Full Text] [Related]
9. ALKBH5-Mediated m6A Demethylation of GLUT4 mRNA Promotes Glycolysis and Resistance to HER2-Targeted Therapy in Breast Cancer.
Liu H; Lyu H; Jiang G; Chen D; Ruan S; Liu S; Zhou L; Yang M; Zeng S; He Z; Wang H; Li H; Zheng G; Liu B
Cancer Res; 2022 Nov; 82(21):3974-3986. PubMed ID: 36069931
[TBL] [Abstract][Full Text] [Related]
10. RNA demethylase ALKBH5 promotes colorectal cancer progression by posttranscriptional activation of RAB5A in an m6A-YTHDF2-dependent manner.
Shen D; Lin J; Xie Y; Zhuang Z; Xu G; Peng S; Tang G; Bai L; Zhu M; Zhang Y; Huang Z; Wang P; Liu X; Huang M; Luo Y; Wang X; Yu H
Clin Transl Med; 2023 May; 13(5):e1279. PubMed ID: 37203239
[TBL] [Abstract][Full Text] [Related]
11. ALKBH5 activates FAK signaling through m6A demethylation in
Sun R; Yuan L; Jiang Y; Wan Y; Ma X; Yang J; Sun G; Zhou S; Wang H; Qiu J; Zhang L; Cheng W
Theranostics; 2023; 13(2):833-848. PubMed ID: 36632222
[No Abstract] [Full Text] [Related]
12. ALKBH5 prevents hepatocellular carcinoma progression by post-transcriptional inhibition of PAQR4 in an m6A dependent manner.
Wang W; Huang Q; Liao Z; Zhang H; Liu Y; Liu F; Chen X; Zhang B; Chen Y; Zhu P
Exp Hematol Oncol; 2023 Jan; 12(1):1. PubMed ID: 36609413
[TBL] [Abstract][Full Text] [Related]
13. Demethylase ALKBH5 suppresses invasion of gastric cancer via PKMYT1 m6A modification.
Hu Y; Gong C; Li Z; Liu J; Chen Y; Huang Y; Luo Q; Wang S; Hou Y; Yang S; Xiao Y
Mol Cancer; 2022 Feb; 21(1):34. PubMed ID: 35114989
[TBL] [Abstract][Full Text] [Related]
14. m
Tang B; Yang Y; Kang M; Wang Y; Wang Y; Bi Y; He S; Shimamoto F
Mol Cancer; 2020 Jan; 19(1):3. PubMed ID: 31906946
[TBL] [Abstract][Full Text] [Related]
15. ALKBH5 inhibits thyroid cancer progression by promoting ferroptosis through TIAM1-Nrf2/HO-1 axis.
Li W; Huang G; Wei J; Cao H; Jiang G
Mol Cell Biochem; 2023 Apr; 478(4):729-741. PubMed ID: 36070054
[TBL] [Abstract][Full Text] [Related]
16. Suppression of m6A mRNA modification by DNA hypermethylated ALKBH5 aggravates the oncological behavior of KRAS mutation/LKB1 loss lung cancer.
Zhang D; Ning J; Okon I; Zheng X; Satyanarayana G; Song P; Xu S; Zou MH
Cell Death Dis; 2021 May; 12(6):518. PubMed ID: 34016959
[TBL] [Abstract][Full Text] [Related]
17. ALKBH5 promotes the proliferation of renal cell carcinoma by regulating AURKB expression in an m
Zhang X; Wang F; Wang Z; Yang X; Yu H; Si S; Lu J; Zhou Z; Lu Q; Wang Z; Yang H
Ann Transl Med; 2020 May; 8(10):646. PubMed ID: 32566583
[TBL] [Abstract][Full Text] [Related]
18.
Zhao X; Zhao Z; Xie H; Gao W; Ye C
Discov Med; 2024 Jan; 36(180):61-70. PubMed ID: 38273746
[TBL] [Abstract][Full Text] [Related]
19. The m6A demethylase ALKBH5 controls trophoblast invasion at the maternal-fetal interface by regulating the stability of
Li XC; Jin F; Wang BY; Yin XJ; Hong W; Tian FJ
Theranostics; 2019; 9(13):3853-3865. PubMed ID: 31281518
[TBL] [Abstract][Full Text] [Related]
20. Decreased
Luo Q; Gao Y; Zhang L; Rao J; Guo Y; Huang Z; Li J
Biomed Res Int; 2020; 2020():5735279. PubMed ID: 32884942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]